---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-271108"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2022-10-27T23:59:59+00:00"
generated_at: "2026-06-23T00:09:42.672515+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Taysha prices $28M public offering of 14M shares at $2.00 per share

## Summary
- Offering of 14M shares at $2.00/share; net proceeds ~$25.6M (or ~$29.6M if over-allotment exercised).
- Underwriter granted 30-day option to purchase up to 2.1M additional shares at $1.88/share.
- Closing expected October 31, 2022; Goldman Sachs & Co. LLC is sole book-runner.
- Proceeds will be used for general corporate purposes; dilution to existing shareholders.

## SEC filing metadata
- accession: 0001193125-22-271108
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2022-10-27T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312522271108/0001193125-22-271108-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312522271108/d421669d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-271108
- JSON: https://secwatch.observer/filing/0001193125-22-271108.json
- Plain text: https://secwatch.observer/filing/0001193125-22-271108.txt

## Key facts
- Material Agreements
  Taysha Gene Therapies, Inc. entered into Underwriting Agreement with Goldman Sachs & Co. LLC (effective 2022-10-26).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Goldman Sachs & Co. LLC
  - Effective: 2022-10-26
  source text: On October 26, 2022, Taysha Gene Therapies, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Goldman Sachs & Co. LLC (the “ Underwriter ”), to issue and sell 14,000,000 shares of common stock of the Company, par value $0.00001 per share (“ Common Stock ”), in an underwritten public offering pursuant to effective registration statements on Form S-3 (File No. 333-260069) and a related prospectus and prospectus supplement, in each case filed with the Securities and Exchange Commission (the “ Offering ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806310/000119312522271108/0001193125-22-271108-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.